About BioMarker Strategies
BioMarker Strategies is a company based in Rockville (United States) founded in 2007. BioMarker Strategies has raised $7.25 million across 14 funding rounds from investors including HHS, National Cancer Institute and NIH SBIR/STTR. BioMarker Strategies offers products and services including SnapPath Cancer Diagnostics System and PathMAP Functional Signaling Profiles. BioMarker Strategies operates in a competitive market with competitors including Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
- Headquarter Rockville, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.25 M (USD)
in 14 rounds
-
Latest Funding Round
$299.34 K (USD), Grant
Sep 22, 2017
-
Investors
HHS
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of BioMarker Strategies
BioMarker Strategies offers a comprehensive portfolio of products and services, including SnapPath Cancer Diagnostics System and PathMAP Functional Signaling Profiles.
Automates profiling of live tumor cells for predictive cancer treatment selection.
Generates predictive profiles from live cells for targeted therapy responses.
People of BioMarker Strategies
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of BioMarker Strategies
BioMarker Strategies has successfully raised a total of $7.25M across 14 strategic funding rounds. The most recent funding activity was a Grant round of $299.34 thousand completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BioMarker Strategies
BioMarker Strategies has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, National Cancer Institute and NIH SBIR/STTR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Cancer research is conducted and supported by the institute.
|
Locked | Locked | Locked |
Investor details for BioMarker Strategies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioMarker Strategies
Investment portfolio details for BioMarker Strategies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BioMarker Strategies
Detailed financials for BioMarker Strategies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biomarker Strategies Comparisons
Peer comparison for BioMarker Strategies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioMarker Strategies
BioMarker Strategies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of BioMarker Strategies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biomarker Strategies
Complete news archive for BioMarker Strategies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioMarker Strategies
BioMarker Strategies was founded in 2007 and raised its 1st funding round 1 year after it was founded.
BioMarker Strategies is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
BioMarker Strategies is a funded company, having raised a total of $7.25M across 14 funding rounds to date.
BioMarker Strategies was founded in 2007 in Rockville, United States, within the biotechnology sector focused on oncology. Cancer diagnostics systems, including SnapPath, are developed to enable predictive tests that guide targeted drug development and treatment selection for patients with solid tumor malignancies. PathMAP functional signaling profiles are generated using this system, serving as biomarker tests to predict individual responses to targeted therapies.
BioMarker Strategies's top competitors include Guardant Health, Juno Therapeutics and Foundation Medicine.
BioMarker Strategies offers SnapPath Cancer Diagnostics System and PathMAP Functional Signaling Profiles.
BioMarker Strategies has 4 investors. Key investors include HHS, National Cancer Institute, NIH SBIR/STTR, and Abell Foundation.